Head and neck squamous cells carcinoma develop in the oral cavity, pharynx and larynx
and have a low 5-year survival rate of approximately 40% due to the resistance of cancer …

Head and neck squamous cell carcinomas (HNSCC) are a group of malignancies that
despite preventative measures and advances in cancer treatments, have a detrimental …

Background Despite the high prevalence of epidermal growth factor receptor (EGFR)
overexpression in head and neck squamous cell carcinomas (HNSCCs), incorporation of …

Background Epidermal growth factor receptor (EGFR) is frequently amplified or
overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically …

Abstract Purpose of Review The efficacy of anti-EGFR therapy is still unfavorable in
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients …

EGFR is frequently overexpressed on several cancers, and two targeted antibodies are FDA
approved but differ by isotype. Cetuximab (IgG1 isotype) has been shown to be effective at …

Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted
anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab …

Immune system deregulation and evasion play a key role in cancers' evolution and
progression, including squamous cell carcinoma of the head and neck (SCCHN) …

Objective To determine if the epidermal growth factor receptor (EGFR)-specific monoclonal
antibodies (mAbs) cetuximab or panitumumab mediate in vitro immune activation against …

Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be
a cornerstone in the management of squamous cell carcinoma of the head and neck …